Compare AJANTA PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DISHMAN PHARMA AJANTA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 22.6 25.1 90.0% View Chart
P/BV x 3.9 3.3 116.3% View Chart
Dividend Yield % 0.9 0.7 136.4%  

Financials

 AJANTA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DISHMAN PHARMA
Mar-16
AJANTA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422374 379.8%   
Low Rs898129 696.4%   
Sales per share (Unadj.) Rs233.5197.8 118.1%  
Earnings per share (Unadj.) Rs44.021.2 207.3%  
Cash flow per share (Unadj.) Rs52.234.7 150.2%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.8 97.6%  
Book value per share (Unadj.) Rs255.1179.9 141.8%  
Shares outstanding (eoy) m88.0280.69 109.1%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.01.3 390.4%   
Avg P/E ratio x26.411.9 222.3%  
P/CF ratio (eoy) x22.27.2 306.8%  
Price / Book Value ratio x4.51.4 325.0%  
Dividend payout %20.59.4 217.1%   
Avg Mkt Cap Rs m102,08120,306 502.7%   
No. of employees `0006.80.8 820.3%   
Total wages/salary Rs m4,3075,355 80.4%   
Avg. sales/employee Rs Th3,022.619,252.7 15.7%   
Avg. wages/employee Rs Th633.46,459.5 9.8%   
Avg. net profit/employee Rs Th569.12,064.1 27.6%   
INCOME DATA
Net Sales Rs m20,55415,961 128.8%  
Other income Rs m211265 79.4%   
Total revenues Rs m20,76516,226 128.0%   
Gross profit Rs m5,6644,103 138.0%  
Depreciation Rs m7211,091 66.1%   
Interest Rs m12944 1.2%   
Profit before tax Rs m5,1432,334 220.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273624 204.1%   
Profit after tax Rs m3,8701,711 226.2%  
Gross profit margin %27.625.7 107.2%  
Effective tax rate %24.826.7 92.6%   
Net profit margin %18.810.7 175.6%  
BALANCE SHEET DATA
Current assets Rs m11,81211,018 107.2%   
Current liabilities Rs m3,7769,517 39.7%   
Net working cap to sales %39.19.4 415.8%  
Current ratio x3.11.2 270.2%  
Inventory Days Days77110 70.0%  
Debtors Days Days8235 234.2%  
Net fixed assets Rs m14,39816,304 88.3%   
Share capital Rs m175161 108.7%   
"Free" reserves Rs m22,27712,907 172.6%   
Net worth Rs m22,45214,516 154.7%   
Long term debt Rs m74,189 0.2%   
Total assets Rs m26,96229,805 90.5%  
Interest coverage x444.33.5 12,801.4%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.5 142.4%   
Return on assets %14.48.9 161.6%  
Return on equity %17.211.8 146.2%  
Return on capital %23.017.5 130.9%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m10,6824,952 215.7%   
Fx outflow Rs m2,102697 301.7%   
Net fx Rs m8,5804,255 201.7%   
CASH FLOW
From Operations Rs m3,7482,786 134.5%  
From Investments Rs m-2,228-1,529 145.7%  
From Financial Activity Rs m-1,475-941 156.7%  
Net Cashflow Rs m45316 14.3%  

Share Holding

Indian Promoters % 73.8 61.4 120.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 12.7 59.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 22.1 76.9%  
Shareholders   20,968 46,261 45.3%  
Pledged promoter(s) holding % 4.4 35.8 12.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  CADILA HEALTHCARE  SANOFI INDIA  ALEMBIC PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 13, 2019 09:49 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - GLENMARK PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS